Aurobindo Pharma in the pink of health

Image
Capital Market
Last Updated : Jun 17 2015 | 12:02 AM IST

Aurobindo Pharma rose 1.16% to Rs 1,291.60 at 12:32 IST on BSE after the company said it has received the final approval from the US Food & Drug Administration to manufacture and market Extended Phenytoin Sodium Capsules USP, 100mg.

The announcement was made after market hours yesterday, 15 June 2015.

Meanwhile, the S&P BSE Sensex was down 89.26 points or 0.34% at 26,497.29.

On BSE, so far 41,000 shares were traded in the counter as against average daily volume of 1.40 lakh shares in the past one quarter.

The stock was volatile. The stock rose as much as 2.59% at the day's high of Rs 1,310 so far during the day. The stock rose 0.55% at the day's low of Rs 1,283.95 so far during the day. The stock had hit a record high of Rs 1,432.10 on 17 April 2015. The stock had hit a 52-week low of Rs 644.65 on 10 July 2014.

The stock had underperformed the market over the past one month till 15 June 2015, sliding 5.54% compared with Sensex's 2.7% fall. The scrip had, however, outperformed the market in past one quarter, advancing 11.35% as against Sensex's 6.72% fall.

The large-cap pharma company has equity capital of Rs 29.20 crore. Face value per share is Re 1.

The approved abbreviated new drug application (ANDA) is bioequivalent and therapeutically equivalent to the reference listed drug product (RLD) Dilantin of Parke-Davis Division of Pfizer Inc.

Phenytoin Sodium Extended Capsules is an anti-epileptic product and indicated for the control of seizures and prevention and treatment of seizures occurring during or following neurosurgery. The product has an estimated market size of $125 million in the United States for the twelve months ended April 2015 according to IMS data.

Aurobindo Pharma's consolidated net profit dropped 19.5% to Rs 403.80 crore on 36.3% growth in net sales to Rs 3143.97 crore in Q4 March 2015 over Q4 March 2014.

Aurobindo Pharma, headquartered at Hyderabad, manufactures generic pharmaceuticals and active pharmaceutical ingredients (APIs).

Powered by Capital Market - Live News

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Jun 16 2015 | 12:22 PM IST

Next Story